CGN Nuclear Technology Development Past Earnings Performance
Past criteria checks 0/6
CGN Nuclear Technology Development's earnings have been declining at an average annual rate of -50.2%, while the Chemicals industry saw earnings growing at 7.8% annually. Revenues have been declining at an average rate of 1.2% per year.
Key information
-50.2%
Earnings growth rate
-49.5%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | -1.2% |
| Return on equity | -13.2% |
| Net Margin | -12.1% |
| Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How CGN Nuclear Technology Development makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 6,436 | -777 | 893 | 240 |
| 31 Dec 23 | 6,353 | -737 | 892 | 235 |
| 30 Sep 23 | 5,006 | -116 | 726 | 225 |
| 30 Jun 23 | 5,494 | -30 | 775 | 215 |
| 31 Mar 23 | 6,207 | 136 | 753 | 221 |
| 31 Dec 22 | 6,945 | 200 | 790 | 231 |
| 30 Sep 22 | 9,005 | 184 | 854 | 251 |
| 30 Jun 22 | 8,980 | 171 | 849 | 241 |
| 31 Mar 22 | 8,532 | 191 | 876 | 234 |
| 31 Dec 21 | 7,999 | 177 | 878 | 238 |
| 30 Sep 21 | 7,389 | 222 | 882 | 231 |
| 30 Jun 21 | 7,020 | 201 | 834 | 240 |
| 31 Mar 21 | 7,148 | 357 | 787 | 239 |
| 01 Jan 21 | 6,652 | 271 | 715 | 223 |
| 30 Sep 20 | 7,101 | 281 | 697 | 221 |
| 30 Jun 20 | 7,094 | 254 | 732 | 223 |
| 31 Mar 20 | 6,763 | 23 | 744 | 213 |
| 31 Dec 19 | 7,022 | 103 | 732 | 213 |
| 30 Sep 19 | 6,650 | 207 | 744 | 222 |
| 30 Jun 19 | 6,795 | 252 | 735 | 205 |
| 31 Mar 19 | 6,645 | 311 | 695 | 199 |
| 31 Dec 18 | 6,776 | 320 | 713 | 193 |
| 30 Sep 18 | 6,764 | 348 | 672 | 178 |
| 30 Jun 18 | 6,503 | 363 | 589 | 198 |
| 31 Mar 18 | 6,546 | 381 | 619 | 157 |
| 31 Dec 17 | 6,363 | 393 | 605 | 126 |
| 30 Sep 17 | 5,341 | 322 | 494 | 60 |
| 30 Jun 17 | 4,504 | 329 | 443 | 0 |
| 31 Mar 17 | 3,619 | 301 | 334 | 0 |
| 31 Dec 16 | 3,015 | 311 | 260 | 0 |
| 30 Sep 16 | 2,659 | 1,287 | 215 | 0 |
| 30 Jun 16 | 2,387 | 1,191 | 185 | 0 |
| 31 Mar 16 | 2,202 | 279 | 224 | 0 |
| 31 Dec 15 | 2,137 | 245 | 219 | 0 |
| 30 Sep 15 | 2,312 | -814 | 273 | 0 |
| 30 Jun 15 | 2,103 | -794 | 300 | 0 |
| 31 Mar 15 | 2,169 | 65 | 251 | 0 |
| 31 Dec 14 | 2,030 | 75 | 257 | 0 |
| 30 Sep 14 | 2,203 | 94 | 241 | 0 |
| 30 Jun 14 | 2,241 | 93 | 240 | 0 |
| 31 Mar 14 | 1,996 | 111 | 232 | 0 |
| 31 Dec 13 | 1,998 | 108 | 230 | 0 |
| 30 Sep 13 | 2,029 | 133 | 258 | 0 |
Quality Earnings: 000881 is currently unprofitable.
Growing Profit Margin: 000881 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000881 is unprofitable, and losses have increased over the past 5 years at a rate of 50.2% per year.
Accelerating Growth: Unable to compare 000881's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000881 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-16.4%).
Return on Equity
High ROE: 000881 has a negative Return on Equity (-13.17%), as it is currently unprofitable.